chevron_leftBack
As of 13 June 2026, Ayala Pharmaceuticals, Inc. has a market cap of $35.79M USD, ranking #32981 globally and #4674 in the United States.
It ranks #2977 in the Healthcare sector, and #574 in the Biotechnology industry.
Key Stats
Market Cap
$35.79MUSD
Revenue (TTM)
$13.0KUSD
EBITDA (TTM)
-$34.9MUSD
Net Income (TTM)
-$48.07MUSD
PS Ratio
2753.3
PB Ratio
-1.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Kenneth Berlin
open_in_new
Employees
21
Founded
1987
Website
ayalapharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 5.9% | 18% | 663% | 1K% | 1K% | 2K% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ADXS
Ayala Pharmaceuticals Inc Ordinary Shares
ISIN: US0076244062
Shares Out.:
Shares Outstanding:
42.633M1
Shares Float:
39.474M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.6036 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
510K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
447K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
77K%
|
-
|
|
NYSE: IQV
|
$26.3B
73K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
70K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
51K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
134K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
125K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
118K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
118K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
78K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
72K%
|
-
|
chevron_leftBack